Chester County News and Community Website
MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX) recently announced the initiation of a clinical study evaluating the safety and pharmacokinetics (PK) of ANJESO (meloxicam) injection in pediatric patients (ages …
Baudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO in Pediatric Patients Following Surgery Read More
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced it recently completed enrollment in its Phase 2 study of lucinactant (KL4 surfactant) for patients with COVID-19 associated lung injury and …
Windtree Completes Enrollment in Its Phase 2 Study of Lucinactant for COVID-19 Associated Lung Injury and Acute Respiratory Distress Syndrome Read More
RADNOR, PA — Idorsia Pharmaceuticals, US Inc. announced the recent publication of “Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase …
The Lancet Neurology Reports Impact of Daridorexant Read More RADNOR, PA — Idorsia Pharmaceuticals, US Inc. announced that the US Food and Drug Administration (FDA) recently approved QUVIVIQ™ (daridorexant) 25 mg and 50 mg for the treatment of adult …
Idorsia Receives FDA Approval of QUVIVIQ for Treatment of Adults with Insomnia Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has provided an update on the status of certain of its clinical programs and on its research and development (R&D) operations.
Aclaris Therapeutics Provides R&D Update Read More
PHILADELPHIA, PA — Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced recent data from its Phase 1/2 clinical trial of investigational SPK-8011 in hemophilia A. …
Spark Therapeutics Updates SPK-8011 Data from Phase 1/2 Study Read More
VILLANOVA, PA — Professor Peter Kaufmann, PhD, FABMR, FSBM, associate dean for Research and Innovation at Villanova University M. Louise Fitzpatrick College of Nursing (FCN), has co-authored with Lynda H. …
Villanova Nursing’s Dr. Peter Kaufmann co-authors Behavioral Clinical Trials for Chronic Diseases Read More
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) recently announced 28-day data from the second dose cohort, at the 100 million cell dose level, in the DesCAARTes™ Phase 1 clinical …
Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes Trial Read More
WASHINGTON, D.C. — The Department of Veterans Affairs’ Office of Research and Development transitioned all its research sites nationwide and its Central Institutional Review Board, June 30, to the IRBNet …
100 Plus VA Medical Centers Implement Electronic Solution to Streamline Research Read More
HORSHAM, PA — Clinical Ink, a global clinical trial technology company, recently announced that CBO Jonathan Andrus has been selected to co-lead the Decentralized Trials & Research Alliance’s (DTRA) Initiative …
Clinical Ink CBO Jonathan Andrus Selected as DTRA Co-Leader Read More